Immunology Investor Event

sanofi NanobodyⓇ molecules enable multi-targeting strategy A strong early clinical pipeline delivering transformative medicines 12-15kDa Anti-HSA Aspirational Profile Break efficacy ceiling anti-IL-13/TSLP Phase I Asthma Broadening patient population anti-Target 1 anti-Target 2 Half-life extension Break efficacy ceiling anti-IL-13/OX40L Phase I AD Durable disease remission Multi-targeting strategy to break efficacy ceilings Break efficacy ceiling anti-TNFα/OX40L Phase I RA Durable disease remission Convenience of dosing Convenience of administration anti-TNFα/IL-23 Phase I UC Break efficacy ceiling Address TNFI non-response Simplified development approach Break efficacy ceiling anti-TNFα/IL-6 Preclinical RA - Favorable economics and Cost of Goods Durable disease remission 45 Immunology Investor Event

View entire presentation